Idiots on parade. Interesting.
WRB, this is a line used by Monkey brains aka munkus. Instead of accusing others of multiple aliases look at yourself. Take your own advice and have no more children. One of you is enough entertainment.
You are right SPHs is not the same; its a piece of garbage compared to NYMX. The company has diluted so many times and even changed its name to hide its past.
My post was about the BPH indication being dormant. If and when prostate cancer trial begins NYMX will be doing a phase three pivotal trail while SPHS will start with a proof of concept trial AKA phase two and will be behind NYMX.
So today after the Recordati announcement NX1207 for BPH is finally laid to rest. The company keeps on hinting at a possible deal for prostate cancer based on its failed/inconclusive prostate cancer phase two trial but nothing as yet. They have been hinting at it for the last one year so I doubt its going to happen anytime soon. Sophiris is in exactly the same situation.
My sympathies and commiserations to the patient, longsuffering investors of both companies.
Thanks. I listened to it. It was not up this morning.
Apart from the trial they said they are discontinuing the development of the drug; so I guess they are handing back the European rights to Nymox.
It will be interesting to know what the results are from the trial so far if NYMOX will ever tell us.
Did you listen to the conference call, if so, can you write what was said. The slides on their website do not give any information. Thanks.
This is the guy who used to come on the NYMOX Board and rub NYMOX investors face in the mud after the NYMOX trial failed.
How does it feel to be on the other side?
This is why I think the EU trails is a big deal, even the placebo patients get Flomax. The only problem is that its only single blind not double blind. In US you need double blind studies.
We can speculate. Typically placebo responders in previous trial have averaged round 5 and the NX1207 patients between 7-8. Typically trials are powered at 80% so I am assuming a two point difference would allow the trial to succeed.
As per Dr. A in the Conf. Call, the drug performed as expected but the placebo was higher and that is what failed the trial. Sheer speculation but assuming say the drug averaged around 7 and the placebo at around 6 ( the drug was superior to the placebo at all times).
They had a number of very high placebo responders; say 20 placebo patients with scores of 25 ie 20 points more than they should have ie an 20 into 20 ie 400 extra points over the placebo group. this translates into an extra point per placebo patient ie 6 instead of 5 per placebo patient.
This is enough to move the trial from success to failure.
This is just speculation but my point is a limited no. of high scoring placebo patients determine the outcome of the trial. If they can be thrown out or as in my previous post some of the low responding patients who took other drugs can be thrown out or a combination of both; the results can change.
Since you know so much tell me what is the current status of the negotiations for prostate cancer for US rights that you talked about in one of your posts.